Date: 2012-03-30
Type of information: R&D agreement
Compound: biomarkers - molecular companion diagnostic test to help identify patients most likely to respond to a novel Sanofi investigational agent
Company: HTG Molecular Diagnostics (USA) Sanofi (France)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: HTG Molecular Diagnostics has established a collaborative program with Sanofi US to identify biomarkers that may lead to the development of a molecular companion diagnostic test to help identify patients most likely to respond to a novel Sanofi investigational agent. HTG Molecular Diagnostics’ qNPA technology measures mRNA and/or miRNA expression in formalin fixed paraffin embedded (FFPE) tumor samples, allowing clinicians to verify the presence of certain biomarkers relevant to patient selection and therapy.
Financial terms:
Latest news:
